KMT2A

Across TCGA pan-cancer cohorts, KMT2A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KMT2A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where KMT2A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KMT2A is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and COAD are the cancer types where KMT2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KMT2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.163	<.001	6	view →
LSCC	All	All	+0.098	<.001	6	view →
COAD	Female	All	−0.187	.008	5	view →
PDAC	Female	All	+0.175	.032	2	view →
LUAD	Female	All	−0.069	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

KMT2A–CCRCC

Open the CCRCC breakdown →